Research Lab Review

Macrocyclic peptides reach the clinic: cholesterol and liver cancer

News

Two 2026 reviews track cyclic peptides in human studies: an oral LDL-lowering drug in phase 3, and PET tracers for liver cancer in first human scans.

Cyclic peptides, chains of amino acids joined into a ring, have long been a topic for chemists. Two reviews published in 2026 describe them being tested in people. One covers enlicitide, a macrocyclic peptide taken by mouth that lowered LDL cholesterol in phase 3 trials [1]. The other covers ring-shaped peptides used to image liver cancer in first-in-human PET studies [2]. Both reviews are also clear about what has not yet been shown.

Key takeaways

  • A review reports that enlicitide, an oral macrocyclic peptide that blocks PCSK9, lowered LDL cholesterol by about 60% more than placebo across three phase 3 trials over 52 weeks [1].
  • Whether enlicitide reduces heart attacks, strokes or deaths is not yet known. Large cardiovascular outcome trials are still running [1].
  • Macrocyclic peptides that bind glypican-3 (GPC3), a protein found on most liver cancers, have reached first-in-human PET imaging studies [2].
  • These imaging studies found that GPC3 levels vary between patients and within a single patient’s tumors. That is a key limit for any therapy aimed at this target [2].

Why make peptides into rings?

A linear peptide is floppy and is quickly broken down by enzymes. Closing it into a ring holds it in a fixed shape. Reviews describe cyclic peptides as “conformationally constrained and chemically adaptable” scaffolds that can block a target directly, carry a drug or radioactive label, or bring two proteins together [4]. In imaging research, cyclization has been linked to better stability in the body and sharper tumor-to-liver contrast in preclinical models [3].

Chemists are still looking for new ways to make these rings. A 2026 laboratory study described a method that joins two lysine side chains in an unmodified peptide with a urea or thiourea bridge [5]. The authors applied it to the targeting peptide RGD and to an analogue of the antimicrobial peptide anoplin [5]. In their lab tests, the thiourea-bridged versions showed stronger target binding, antitumor activity, better membrane permeability and greater stability than the starting peptides [5]. The abstract does not state the size or design of these tests, and the results come from laboratory work, not people [5]. Other groups find new cyclic peptides by expressing large genetically encoded libraries inside cells and selecting those that block a chosen target, an approach a separate review summarizes [6].

Enlicitide: an oral PCSK9 blocker in phase 3

PCSK9 is a protein that lowers the number of LDL receptors on liver cells. With fewer receptors, more LDL cholesterol stays in the blood [1]. Existing drugs that block PCSK9 are given by injection. The review in Current Opinion in Lipidology looks at oral PCSK9 inhibitors that have reached phase 2 or later [1].

What kind of evidence: a narrative review of clinical trial results [1]. The abstract does not give the number of participants in each trial.

What it reports: Enlicitide is a macrocyclic peptide that competes with the LDL receptor for binding to PCSK9 [1]. Across three phase 3 trials, it lowered LDL cholesterol by about 60% compared with placebo [1]. The review describes high adherence and a favorable safety profile over 52 weeks [1].

The review also covers laroprovstat, a small molecule rather than a peptide. It works by a different mechanism, interfering with PCSK9-driven trafficking of the LDL receptor to lysosomes [1]. In a phase 2 trial, it lowered LDL cholesterol by up to 51%, with larger effects at higher doses, and it is now in phase 3 [1].

Limits: LDL cholesterol is a lab marker, not an outcome patients feel. The cardiovascular outcome trials for both drugs are still underway [1]. The safety data cover 52 weeks, which is short for a drug that might be used for many years [1]. The authors add that real-world uptake will depend on affordability, insurance coverage, clinician adoption and long-term adherence. A trial result alone does not settle those questions [1].

Glypican-3 peptides for liver cancer imaging

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. GPC3 is a protein on the cell surface that is highly expressed in most HCC tumors. It is absent or nearly absent in normal adult liver and in cirrhosis [2]. That contrast makes it a candidate target for both imaging and therapy, an approach called “theranostics” [2].

What kind of evidence: a review in the Journal of Nuclear Medicine that summarizes early clinical imaging studies [2]. The abstract does not give patient numbers.

What it reports: Early human PET studies used radiolabeled full-size antibodies. They showed that GPC3 can be seen on scans. They also showed that large antibodies clear slowly, which is a problem for imaging the liver [2]. Smaller formats, including antibody fragments, single-domain antibodies and macrocyclic peptides, improved image contrast at earlier time points [2]. These formats made first-in-human PET studies possible in people with HCC and with hepatoblastoma, a childhood liver cancer [2].

The review notes that a phase 1 trial is ongoing [2]. It uses a GPC3-binding macrocyclic peptide labeled with actinium-225, a radioactive isotope meant to damage tumor cells [2]. Patients are selected for that trial using a gallium-68 PET version of the same peptide [2]. A separate actinium-225-labeled GPC3 antibody is in phase 1/2 testing [2]. Neither trial has reported results in the abstract.

Limits: These are early feasibility studies. They show that tumors can be imaged, not that imaging or therapy improves survival [2]. The studies also found GPC3 expression varies between patients and within the same patient [2]. The authors say this is why GPC3 should be imaged before any GPC3-targeted therapy is given [2].

The preclinical pipeline behind the tracers

A second review, in the Journal of Peptide Science, traces two decades of linear and cyclic GPC3-binding peptides [3]. Most were found by phage display, rational optimization or structure-guided design [3].

What kind of evidence: a topical review of mainly preclinical work [3]. These peptides have enabled PET, SPECT and fluorescence imaging of HCC in preclinical models, not in people [3].

What it reports: The authors argue that peptides have advantages over antibodies for imaging. These include small size, faster tumor penetration, quicker clearance and easier chemical modification [3]. They say antibodies are limited by large size, slow pharmacokinetics and possible immune reactions [3]. Adding an albumin-binding group and cyclizing the peptide both improved tumor-to-liver contrast and stability in the body in these models [3].

Limits: Results in animal models do not show how the probes will perform in patients. The review names AI and machine-learning design of new ligands as a future direction, not a proven one [3].

The same theme appears in kidney cancer research. A review of cyclic peptides for renal cell carcinoma names target heterogeneity, linker stability, pharmacokinetics and kidney distribution as open challenges [4]. It concludes that clinical evidence for therapy “remains limited” [4].

What we still don’t know

  • Hard outcomes for enlicitide. About 60% LDL lowering is a large effect on a lab marker, but outcome trials have not yet reported effects on cardiovascular events [1].
  • Long-term safety and adherence. The phase 3 data cover 52 weeks [1]. Adherence in trials may not match everyday use [1].
  • Access. Cost, payer coverage and clinician uptake will shape whether an oral option changes practice [1].
  • Whether GPC3 peptides help patients. Imaging feasibility is established in early studies, but the radioactive therapy version is still in phase 1 [2].
  • Target heterogeneity. GPC3 levels differ between and within patients, so not every tumor, or every part of a tumor, may be reached [2]. Similar concerns apply to other cyclic-peptide targets [4].
  • Lab-to-clinic gap. New cyclization chemistry and selection methods show promise in laboratory work [5, 6], but most cyclic peptides described in these reviews have not been tested in people [3, 4].

References

  1. Oral PCSK9 inhibitors: closing the gap between potency and practicality. Current Opinion in Lipidology (2026). doi:10.1097/MOL.0000000000001061
  2. Glypican-3 as a Theranostic Target in Hepatocellular Carcinoma. Journal of Nuclear Medicine (2026). doi:10.2967/jnumed.126.272814
  3. Beyond Antibodies: Glypican‐3‐Targeting Peptides for Precision Hepatocellular Carcinoma Theranostics. Journal of Peptide Science (2026). doi:10.1002/psc.70134
  4. Recent Advances in Cyclic Peptide-Based Therapeutic Strategies for Renal Cell Carcinoma: A Focused Review. Drug Design, Development and Therapy (2026). doi:10.2147/DDDT.S638461
  5. Macrocyclization of native peptides through (thio)urea crosslinking of two amines. Nature Communications (2026). doi:10.1038/s41467-026-77301-w
  6. De Novo Discovery of Bioactive Cyclic Peptides via Cellular Selection of Genetically Encoded Libraries. ChemBioChem (2026). doi:10.1002/cbic.70532

Image credits

Free to use (CC0 / public domain); credited as a courtesy.

  • Large-Animal PET-CT Imaging System (NIH BioArt 696 – 782759).png, by Courtesy of NIAID

Malcolm Houston (Public domain, via wikimedia-commons): https://commons.wikimedia.org/wiki/File:Large-Animal_PET-CT_Imaging_System_(NIH_BioArt_696_-_782759).png